NCT04132505 2026-04-06
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
41 trialsNCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
NCT03037437 2025-09-04
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01506973 2025-07-25
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT03377179 2025-07-23
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
RedHill Biopharma Limited
Phase 2 Completed
NCT04011410 2025-04-11
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
University of Kentucky
Phase 2 Completed
NCT04735068 2025-04-01
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT03774472 2025-02-17
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04386057 2025-02-12
LY3214996 +/- HCQ in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04145297 2024-11-18
UTAH
University of Utah
Phase 1 Completed
NCT02316340 2024-01-05
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT03513211 2023-11-22
HITMAN-PC
St Vincent's Hospital, Sydney
Phase 1/2 Completed
NCT03215264 2023-11-09
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00813423 2023-08-02
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT04593758 2023-05-24
To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Cornerstone Pharmaceuticals
Phase 1/2 Completed
NCT01023737 2023-02-13
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Completed
NCT01649947 2022-11-21
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT00962845 2022-09-07
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Completed
NCT00726596 2022-06-16
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT03449758 2022-04-28
SariPRO
Sanofi
Phase 4 Completed
NCT04163107 2022-03-18
MYELOMA-HCQ
Norwegian University of Science and Technology
Phase 1 Completed
NCT03015324 2022-01-25
Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors
University of Kentucky
Phase 1 Completed
NCT01006369 2021-09-21
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT02232243 2021-06-28
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
University of Kentucky
Phase 1 Completed
NCT03081702 2021-04-02
A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer
University Health Network, Toronto
Phase 1/2 Completed
NCT01266057 2021-03-04
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01897116 2020-05-29
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00568880 2020-02-07
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT00486603 2019-07-10
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01128296 2019-05-01
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
University of Pittsburgh
Phase 1/2 Completed
NCT01206530 2019-04-18
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT00909831 2019-04-16
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01978184 2019-03-27
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
University of Pittsburgh
Phase 2 Completed
NCT01687179 2018-10-11
SAIL
Brigham and Women's Hospital
Phase 1 Completed
NCT01602588 2018-05-03
HCQ
University College, London
Phase 2 Completed
NCT01689987 2017-09-07
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 1 Completed
NCT01273805 2017-06-14
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01634893 2016-03-25
Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Completed
NCT00714181 2016-02-18
Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01396200 2013-02-26
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed